Marina Konopleva - Concepedia

Author

Marina Konopleva

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Jose Halperin, Konopleva, M., Konopleva, Marina, M Konopleva, M Y Konopleva, M. Konopleva, M.Y. Konopleva, Marina Konopleva, Marina Konopleva MD, PhD, Marina Y Konopleva

2.1K

Publications

69.4K

Citations

130

H-Index

153

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute University of California, Irvine The University of Texas Health Science Center at Houston Albert Einstein College of Medicine

About

Marina Konopleva is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	75	196	21.6K
2	Health Sciences	41	77	7.8K
3	Engineering	6	6	567
4	Natural Sciences	3	3	93
5	Anatomy	1	1	19

Marina Konopleva

635

Publications

59.6K

Citations

121

H-Index

Page 1

	Year	Citations
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, New England Journal of Medicine	2020	2.6K
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Blood	2018	1.8K
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner, New England Journal of Medicine	2014	1.4K
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Cancer Discovery	2016	1K
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia Marina Konopleva, Rooha Contractor, Twee Tsao, Cancer Cell Hematological MalignancyMedicineAcute Myeloid LeukemiaApoptosisHematology	2006	1K
An inhibitor of oxidative phosphorylation exploits cancer vulnerability Jennifer R. Molina, Yuting Sun, Marina Protopopova, Nature Medicine MedicineAnti-cancer AgentCancer VulnerabilityPharmacologyTumor Microenvironment	2018	903
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Rongqing Pan, Leah J. Hogdal, Juliana M. Benito, Cancer Discovery	2013	717
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study Courtney D. DiNardo, Keith W. Pratz, Anthony Letai, The Lancet Oncology Hematological MalignancyOncologyElderly PatientsMixed-phenotype Acute LeukemiaHematology	2018	692
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction Ismael Samudio, Romain Harmancey, Michael Fiegl, Journal of Clinical Investigation Pharmacologic InhibitionLipid PeroxidationApoptosisCell DeathLeukemia Cells	2009	689
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666

Page 1